Brian Dougherty

30.8k total citations · 4 hit papers
60 papers, 5.0k citations indexed

About

Brian Dougherty is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Brian Dougherty has authored 60 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 26 papers in Oncology and 19 papers in Genetics. Recurrent topics in Brian Dougherty's work include PARP inhibition in cancer therapy (18 papers), Cancer Genomics and Diagnostics (15 papers) and BRCA gene mutations in cancer (11 papers). Brian Dougherty is often cited by papers focused on PARP inhibition in cancer therapy (18 papers), Cancer Genomics and Diagnostics (15 papers) and BRCA gene mutations in cancer (11 papers). Brian Dougherty collaborates with scholars based in United States, United Kingdom and Australia. Brian Dougherty's co-authors include J. Carl Barrett, I van de Rijn, Zhongwu Lai, Aleksandra Markovets, Daniel Stetson, Darren Hodgson, Michael Friedländer, Maria Orr, Pasi A. Jänne and Jonathan A. Ledermann and has published in prestigious journals such as Science, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Brian Dougherty

58 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

2015 1.2k citations Daniel Stetson, Brian Dougherty et al. profile →
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

2014 1.1k citations Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology profile →
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

2016 497 citations Zhongwu Lai, Aleksandra Markovets et al. profile →
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

2014 426 citations Brian Dougherty, J. Carl Barrett et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian Dougherty United States	25	2.5k	2.4k	1.3k	1.1k	960	60	5.0k
Maria I. Harrell United States	24	1.9k 0.8×	2.4k 1.0×	233 0.2×	528 0.5×	883 0.9×	46	5.6k
Paul B. Mullan United Kingdom	31	1.3k 0.5×	2.0k 0.8×	381 0.3×	768 0.7×	210 0.2×	70	3.7k
Karl Ziegelbauer Germany	43	1.0k 0.4×	2.4k 1.0×	567 0.4×	511 0.5×	44 0.0×	122	4.9k
Raffit Hassan United States	51	4.1k 1.6×	2.1k 0.9×	3.9k 3.0×	399 0.4×	260 0.3×	184	9.9k
Julian Gannon United Kingdom	30	3.4k 1.4×	4.0k 1.6×	368 0.3×	829 0.8×	110 0.1×	54	6.2k
Richard Iggo Switzerland	42	4.6k 1.8×	4.8k 2.0×	794 0.6×	2.0k 1.9×	101 0.1×	95	8.2k
G Riou France	37	2.0k 0.8×	2.6k 1.1×	232 0.2×	692 0.6×	149 0.2×	123	4.4k
Hiroyuki Marusawa Japan	43	1.5k 0.6×	2.9k 1.2×	569 0.4×	1.3k 1.3×	39 0.0×	160	7.1k
Paul H. Gumerlock United States	41	3.0k 1.2×	2.4k 1.0×	3.3k 2.5×	1.1k 1.0×	33 0.0×	146	5.9k
James L. Murray United States	41	2.6k 1.0×	2.0k 0.8×	639 0.5×	657 0.6×	60 0.1×	176	5.8k

Countries citing papers authored by Brian Dougherty

Since Specialization

Citations

This map shows the geographic impact of Brian Dougherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Dougherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Dougherty more than expected).

Fields of papers citing papers by Brian Dougherty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Dougherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Dougherty. The network helps show where Brian Dougherty may publish in the future.

Co-authorship network of co-authors of Brian Dougherty

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Dougherty. A scholar is included among the top collaborators of Brian Dougherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Dougherty. Brian Dougherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Auth, Roger, et al.. (2025). Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis–Related Diabetes and Metabolic Syndrome. PubMed. 12(2). 67–70.

Nuttall, Barrett, Daniel Karl, Kathleen A. Burke, et al.. (2025). Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples. Clinical Epigenetics. 17(1). 156–156.

Roschewski, Mark, Manish R. Patel, Patrick M. Reagan, et al.. (2023). Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. Clinical Cancer Research. 29(17). 3301–3312. 13 indexed citations

Stetson, Daniel, Gregory T. Jones, Giovanni Marsico, et al.. (2023). Abstract 3384: Evaluation of a tumor informed MRD assay with contrived breast cancer samples. Cancer Research. 83(7_Supplement). 3384–3384. 1 indexed citations

Munugalavadla, Veerendra, Aleksandra Markovets, Qin‐Wen Liu, et al.. (2023). Abstract 3369: Utility of ctDNA-based targeted methylation MRD assay for hematological malignancies. Cancer Research. 83(7_Supplement). 3369–3369. 2 indexed citations

Hodgson, Darren, Brian Dougherty, Zhongwu Lai, et al.. (2018). Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. British Journal of Cancer. 119(11). 1401–1409. 167 indexed citations

Fielding, Anitra, Jordi Bertrán-Alamillo, Brian Dougherty, et al.. (2017). Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. Annals of Oncology. 28. v626–v626. 3 indexed citations

Rodríguez‐Vida, Alejo, Matilde Saggese, Simon Hughes, et al.. (2015). Complexity of FGFR signalling in metastatic urothelial cancer. Journal of Hematology & Oncology. 8(1). 119–119. 23 indexed citations

Jänne, Pasi A., Ian C. P. Smith, Gael McWalter, et al.. (2015). Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. British Journal of Cancer. 113(2). 199–203. 59 indexed citations

10.

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2014). Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer. Obstetrical & Gynecological Survey. 69(10). 594–596. 14 indexed citations

11.

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2014). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology. 15(8). 852–861. 1060 indexed citations breakdown →

12.

Guinney, Justin, Charles Ferté, Jonathan R. Dry, et al.. (2013). Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. Clinical Cancer Research. 20(1). 265–272. 30 indexed citations

13.

Walsh, William E., Brian Dougherty, David J. Reisberg, et al.. (2008). The Importance of Auricular Prostheses for Speech Recognition. Archives of Facial Plastic Surgery. 10(5). 321–328. 4 indexed citations

14.

Carroll, Pamela M., et al.. (2003). Model systems in drug discovery: chemical genetics meets genomics. Pharmacology & Therapeutics. 99(2). 183–220. 38 indexed citations

15.

Dougherty, Thomas J., et al.. (2001). Efflux in bacteria: what do we really know about it?. Expert Opinion on Investigational Drugs. 10(8). 1409–1422. 67 indexed citations

16.

Read, Timothy D., Steven R. Gill, Hervé Tettelin, & Brian Dougherty. (2001). Finding drug targets in microbial genomes. Drug Discovery Today. 6(17). 887–892. 27 indexed citations

17.

Nelson, Kenrad E., D. L. Richardson, & Brian Dougherty. (1997). Tn 916 Transposition in Haemophilus influenzae Rd: Preferential Insertion into Noncoding DNA. PubMed. 2(4). 313–321. 9 indexed citations

18.

Crater, Dinene L., Brian Dougherty, & I van de Rijn. (1995). Molecular Characterization of hasC from an Operon Required for Hyaluronic Acid Synthesis in Group A Streptococci DEMONSTRATION OF UDP-GLUCOSE PYROPHOSPHORYLASE ACTIVITY. Journal of Biological Chemistry. 270(48). 28676–28680. 106 indexed citations

19.

Dougherty, Brian & I van de Rijn. (1994). Molecular characterization of hasA from an operon required for hyaluronic acid synthesis in group A streptococci.. Journal of Biological Chemistry. 269(1). 169–175. 124 indexed citations

20.

Dougherty, Brian & I van de Rijn. (1992). Molecular characterization of a locus required for hyaluronic acid capsule production in group A streptococci.. The Journal of Experimental Medicine. 175(5). 1291–1299. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact